OpenClinica's Strategic Move: Enhancing Patient Recruitment Efforts
OpenClinica's Acquisition of BuildClinical
In a significant strategic move, OpenClinica has acquired BuildClinical, a leader in patient recruitment solutions for academic researchers. This acquisition signals a pivotal moment in the growth trajectory of both companies and aligns them in their mission to enhance the clinical trial process. OpenClinica, known for its eClinical software solutions, is a proud portfolio company of Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis.
Enhancing Recruitment Solutions
The integration of OpenClinica and BuildClinical will create a holistic suite of solutions that streamline recruitment, consent, enrollment, and data capture for clinical trial participants. BuildClinical’s proficiency in academic research recruitment significantly bolsters OpenClinica’s nearly twenty years of experience supporting clinical trials at academic medical centers. This merger not only enhances the service offerings for clients but also expands the reach of BuildClinical’s innovative recruitment solutions to a broader audience.
OpenClinica's Commitment to Innovation
Cal Collins, Co-Founder and CEO of OpenClinica, expressed pride in this new partnership, highlighting the shared commitment to improving clinical trial data quality and efficiency. He stated, “By aligning with the customer-focused team at BuildClinical, we aim to accelerate recruitment and provide our clients with the tools they need to optimize their studies.” This statement underscores OpenClinica's dedication to delivering cutting-edge solutions and fostering a culture of excellence in clinical research.
Benefits for Clinical Trial Clients
Having worked closely in the clinical trial space, both organizations understand the complexities and challenges faced by researchers. Benji Hochberger, Founder and CEO at BuildClinical, noted, “The synergy created through this partnership will be invaluable for our clients. Our strengths complement each other perfectly, ensuring that patients are efficiently recruited and screened for clinical trials.” This collaboration aims to enhance patient engagement and streamline the trial process, ultimately leading to better research outcomes.
The Role of TSCP
Thompson Street Capital Partners plays a crucial role in this merger, as Matt Scherrer, Managing Director at TSCP, emphasized the importance of academic researchers in developing life-saving treatments. He remarked, “We are excited to support these two organizations as they combine forces to advance clinical research.” TSCP’s commitment to enhancing human quality of life through its investments illustrates the profound impact such partnerships can have on the healthcare landscape.
Future Prospects
As BuildClinical and OpenClinica combine their unique strengths, they are poised to reshape the clinical trial landscape. By focusing on enhanced recruitment methods and robust data management, they will improve accessibility for researchers and participants alike. This partnership holds great promise for the future of clinical research, paving the way for more efficient trials and better patient outcomes. The comprehensive approach to clinical trial management offered by these two companies will certainly raise the bar in the industry.
Frequently Asked Questions
What does the acquisition of BuildClinical by OpenClinica mean for clinical trials?
This acquisition is expected to streamline patient recruitment and improve the trial process, making it more efficient for researchers.
How will this merger impact patient recruitment?
OpenClinica and BuildClinical will provide a comprehensive solution that enhances patient engagement and streamlines the recruitment process for clinical trials.
What is the role of Thompson Street Capital Partners in this acquisition?
Thompson Street Capital Partners is the private equity firm backing OpenClinica and plays a crucial role in supporting the growth and development of both companies.
Who are the leaders of OpenClinica and BuildClinical?
Cal Collins is the Co-Founder and CEO of OpenClinica, while Benji Hochberger is the Founder and CEO of BuildClinical.
What is the primary focus of BuildClinical?
BuildClinical specializes in patient recruitment for clinical research, particularly targeting academic researchers to enhance their recruitment efforts.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.